二肽基肽酶IV作为甲状腺乳头状癌的预后标志物和治疗靶点
本研究通过组织芯片免疫组化、体外功能实验、基因表达与通路分析及小鼠异种移植模型,探讨二肽基肽酶IV(DPP4)在甲状腺癌中的表达与功能。结果显示,在甲状腺乳头状癌中高DPP4表达与甲状腺外侵犯(P < 0.001)、BRAF突变(P < 0.001)及晚期肿瘤分期(P = 0.007)相关。结论认为,DPP4表达升高与细胞侵袭及更具侵袭性的疾病相关,靶向DPP4可能成为表达DPP4的甲状腺癌的治疗策略。
要点
- 在甲状腺乳头状癌中,高DPP4表达与甲状腺外侵犯(P < 0.001)、BRAF突变(P < 0.001)及晚期肿瘤分期(P = 0.007)相关。
- 高DPP4表达组患者在末次随访时被归类为无疾病证据的可能性较低(P = 0.042)。
- DPP4沉默或DPP4抑制剂处理显著抑制集落形成、细胞迁移和侵袭;西格列汀在体内减少肿瘤生长及异种移植瘤转化生长因子-β受体I表达。
核心结论
- DPP4表达升高与甲状腺乳头状癌的细胞侵袭及更具侵袭性的疾病相关。
- 靶向DPP4可能成为表达DPP4的甲状腺癌的治疗策略。
研究设计与样本
- 通过甲状腺肿瘤组织芯片免疫组化检测DPP4表达。
- 在遗传学和药理学抑制DPP4后进行体外功能研究。
- 采用基因表达与通路分析识别下游靶点。
- 在小鼠异种移植模型中评估DPP4抑制的治疗潜力。
主要发现
- 在甲状腺乳头状癌中,高DPP4表达与甲状腺外侵犯(P < 0.001)、BRAF突变(P < 0.001)及晚期肿瘤分期(P = 0.007)相关。
- 高DPP4表达组患者在末次随访时被归类为无疾病证据的可能性较低(P = 0.042)。
- DPP4沉默或DPP4抑制剂处理显著抑制集落形成、细胞迁移和侵袭。
- DPP4敲低后差异表达基因分析提示转化生长因子-β信号通路参与其中。
- 体内实验显示,西格列汀处理减少肿瘤生长及异种移植瘤转化生长因子-β受体I表达。
临床怎么用
- 作者认为,靶向DPP4可能成为表达DPP4的甲状腺癌的治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Dipeptidyl peptidase IV (DPP4) is overexpressed in thyroid cancer and certain malignancies. Furthermore, DPP4 has been identified as a discriminatory marker for thyroid cancer. However, it remains unclear whether DPP4 expression plays a prognostic role. OBJECTIVE: The aim of this study was to investigate the expression and function of DPP4 in thyroid cancer and the mechanisms involved. DESIGN: We determined the expression of DPP4 by immunohistochemistry in tissue microarrays of thyroid tumors. In vitro functional studies were performed after genetic and pharmacological inhibition of DPP4. Gene expression and pathway analyses were used to identify downstream targets. The therapeutic potential of DPP4 inhibition was evaluated in a mouse xenograft model. RESULTS: High DPP4 expression was associated with extrathyroidal extension (P < 0.001), BRAF mutation (P < 0.001), and advanced tumor stage (P = 0.007) in papillary thyroid cancer. Patients in the high-DPP4 expression group were less likely to be classified as having no evidence of disease at final follow-up (P = 0.042). DPP4 silencing or treatment with DPP4 inhibitors significantly suppressed colony formation, cell migration, and invasion. Analysis of differentially expressed genes after DPP4 knockdown suggested that the transforming growth factor-β signaling pathway is involved. In vivo experiments revealed that sitagliptin treatment reduced tumor growth and xenograft transforming growth factor-β receptor I expression. CONCLUSIONS: Increased DPP4 expression is associated with cellular invasion and more aggressive disease in papillary thyroid cancer. Targeting DPP4 may be a therapeutic strategy for DPP4-expressing thyroid cancer.
引用
- Lee JJ, Wang TY, Liu CL, et al. Dipeptidyl Peptidase IV as a Prognostic Marker and Therapeutic Target in Papillary Thyroid Carcinoma. J Clin Endocrinol Metab. 2017. PMID: 28575350. doi:10.1210/jc.2017-00346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。